Headlines about Fibrocell Science (NASDAQ:FCSC) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fibrocell Science earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.9513720535448 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news stories that may have effected Accern’s scoring:

FCSC has been the subject of a number of recent research reports. Zacks Investment Research cut Fibrocell Science from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. ValuEngine cut Fibrocell Science from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.70 target price on shares of Fibrocell Science in a report on Friday, June 9th.

Fibrocell Science (NASDAQ FCSC) traded down 2.24% during trading on Monday, reaching $2.62. The company had a trading volume of 31,647 shares. Fibrocell Science has a 52 week low of $1.57 and a 52 week high of $4.64. The firm’s market capitalization is $38.50 million. The company’s 50-day moving average is $3.61 and its 200 day moving average is $2.24.

Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. Equities analysts anticipate that Fibrocell Science will post ($1.39) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Fibrocell Science (NASDAQ:FCSC) Stock Price” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-fibrocell-science-nasdaqfcsc-stock-price/1487833.html.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Insider Buying and Selling by Quarter for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.